Tung Nadine, Garber Judy E
Beth Israel Deaconess Medical Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
NPJ Breast Cancer. 2022 Apr 8;8(1):47. doi: 10.1038/s41523-022-00411-3.
PARP inhibitors have been approved for the treatment of metastatic breast cancer in germline mutation (gm) carriers. The recent OlympiA trial demonstrated improved progression-free and distant disease-free survival with adjuvant olaparib for gm carriers with HER2-negative high-risk early-stage breast cancer. The current article addresses some for the questions raised by OlympiA regarding how to incorporate PARP inhibitors into the treatment of early-stage breast cancer as well as future directions for PARP inhibitors in breast cancer treatment and prevention.
聚（ADP-核糖）聚合酶（PARP）抑制剂已被批准用于治疗携带种系突变（gm）的转移性乳腺癌。最近的OlympiA试验表明，对于HER2阴性的高危早期乳腺癌的gm携带者，辅助使用奥拉帕尼可改善无进展生存期和远处无病生存期。本文探讨了OlympiA试验提出的一些问题，涉及如何将PARP抑制剂纳入早期乳腺癌的治疗，以及PARP抑制剂在乳腺癌治疗和预防方面的未来发展方向。
